IP Library Granted Patent US 8,735,124
Granted Patent B2
US 8,735,124 · App. 13/420,920 · Granted May 27, 2014

Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage

Inventors: Dan S. Tawfik (Jerusalem, IL); Rinkoo Devi Gupta (Rehovot, IL); Moshe Goldsmith (Rehovot, IL); Yaacov Ashani (Rehovot, IL)
Assignee: Yeda Research and Development Co. Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,735,124
App. No.
13/420,920
Granted
May 27, 2014
Kind
B2
Abstract

An isolated polypeptide comprising the amino acid sequence of serum paraoxonase (PON1) having catalytic efficiency of k cat /K M ≈10 6 -5·10 7 M −1 min −1 for a G-type organophosphate.

Claims (16)

1. An isolated polypeptide comprising an amino acid sequence of a variant serum paraoxonase (PON1) selected from the group consisting of SEQ ID NO: 2, 129, 140, 141 and 142, said isolated polypeptide having hydrolase catalytic efficiency of k cat /k M ≈10 6 -5·10 7 M −1 min −1 for a G-type organophosphate.

2. The isolated polypeptide of claim 1 being expressible in bacteria.

3. An isolated synthetic complimentary DNA (cDNA) polynucleotide comprising a nucleic acid sequence encoding the polypeptide of claim 1 .

4. A pharmaceutical composition comprising as an active ingredient the isolated polypeptide of claim 1 and a pharmaceutically acceptable carrier.

5. A nucleic acid construct comprising the isolated synthetic cDNA of claim 3 and a cis-regulatory element driving expression of said polynucleotide.

6. A method of treating an organophosphate exposure associated damage in a subject, comprising administering to the subject a therapeutically effective amount of the isolated polypeptide of claim 1 .

7. An article of manufacture for treating or preventing organophosphate exposure-associated damage, the article of manufacture comprising the isolated polypeptide of claim 1 immobilized on to a solid support.

8. The article of manufacture of claim 7 , wherein said solid support is for topical administration.

9. The article of manufacture of claim 8 , wherein said solid support for topical administration is selected from the group consisting of a sponge, a wipe and a fabric.

10. The article of manufacture of claim 7 , wherein said solid support is selected from the group consisting of a filter, a fabric and a lining.

11. A method of detoxifying a surface, the method comprising contacting the surface with the isolated polypeptide of claim 1 , thereby detoxifying the surface.

12. The isolated polypeptide of claim 1 comprising the amino acid sequence of SEQ ID NO: 140.

13. The isolated polypeptide of claim 1 , comprising SEQ ID NO: 129.

14. The isolated polypeptide of claim 1 , comprising SEQ ID NO: 141.

15. The isolated polypeptide of claim 1 , comprising SEQ ID NO: 142.

16. The isolated polypeptide of claim 1 , comprising SEQ ID NO: 2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2012
From: TAWFIK, DAN S.; GUPTA, RINKOO DEVI; GOLDSMITH, MOSHE; ASHANI, YAACOV
To: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Reel/Frame 028284/0943 →
Continuity (3)
Continuation In Part PCTIL2010000754 · Sep 15, 2010
Provisional Application 61272363 · Sep 17, 2009
Related Publication 20120213834A1 · Aug 23, 2012